- Full Year 2023 MorphoSys AG Earnings Call TranscriptMar 14, 2024€66.04 (-0.39%)Earnings
- MorphoSys AG to be Acquired by Novartis AG Call TranscriptFeb 06, 2024
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- MorphoSys AG at ASH Meeting and Exposition TranscriptDec 11, 2023
- MorphoSys AG to Discuss MANIFEST-2 Results TranscriptNov 21, 2023
- Q3 2023 MorphoSys AG Earnings Call TranscriptNov 16, 2023€23.35 (-11.22%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Half Year 2023 MorphoSys AG Earnings Call TranscriptAug 10, 2023€28.06 (+2.22%)Earnings
- MorphoSys AG Investor Call Focused on Pelabresib TranscriptJun 21, 2023
- MorphoSys AG at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 MorphoSys AG Earnings Call TranscriptMay 04, 2023€20.14 (+8.86%)Earnings
- Full Year 2022 MorphoSys AG Earnings Call TranscriptMar 16, 2023€14.64 (+7.37%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 MorphoSys AG Earnings Call TranscriptNov 17, 2022€15 (+4.17%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 MorphoSys AG Earnings Call TranscriptAug 04, 2022€22.14 (-2.94%)Earnings
- MorphoSys AG at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 MorphoSys AG Earnings Call TranscriptMay 05, 2022€19.29 (-0.87%)Earnings
- Full Year 2021 MorphoSys AG Earnings Call TranscriptMar 17, 2022€24.56 (+2.59%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2022
- Q3 2021 MorphoSys AG Earnings Call TranscriptNov 11, 2021€37.39 (-2.63%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- MorphoSys AG at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Half Year 2021 MorphoSys AG Earnings Call TranscriptJul 29, 2021€47.34 (+4.85%)Earnings
- MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call TranscriptJun 02, 2021
- MorphoSys AG at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Q1 2021 MorphoSys AG Earnings Call TranscriptMay 06, 2021€72.5 (+2.06%)Earnings
- Full Year 2020 MorphoSys AG Earnings Call TranscriptMar 16, 2021€75.02 (-10.61%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Q3 2020 MorphoSys AG Earnings Call TranscriptNov 12, 2020€88.16 (-1.17%)Earnings
- MorphoSys AG and Incyte Corp to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Investor Call TranscriptSep 29, 2020
- Half Year 2020 MorphoSys AG Earnings Call TranscriptAug 06, 2020€109.8 (-5.26%)Earnings
- MorphoSys AG at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Q1 2020 MorphoSys AG Earnings Call TranscriptMay 07, 2020€113 (+10.46%)Earnings
- Full Year 2019 MorphoSys AG Earnings Call TranscriptMar 19, 2020€72.2 (+2.85%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call TranscriptJan 13, 2020
- Q3 2019 Morphosys AG Earnings Call TranscriptOct 30, 2019€99.1 (+4.21%)Earnings
- Half Year 2019 Morphosys AG Earnings Call TranscriptAug 07, 2019€109 (+4.81%)Earnings
- Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call TranscriptMay 20, 2019
- Q1 2019 Morphosys AG Earnings Call TranscriptMay 08, 2019€95.4 (+5.41%)Earnings
- Full Year 2018 Morphosys AG Earnings Call TranscriptMar 14, 2019€87.05 (+0.23%)Earnings
MorphoSys AG Investor Call Focused on Pelabresib Transcript
Ladies and gentlemen, good morning and good afternoon. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys. And it is my pleasure to welcome you to today's investor call that will focus on the potential of Pelabresib, our investigational BET inhibitor in myeloproliferative neoplasms.
Before we begin, I'd like to remind you on Slide 2 that some of our statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys 20-F and annual report, all for the year ended December 31, 2022, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements on this webcast speak as of today.
I would now like to turn the call over to Jean-Paul Kress, our Chief Executive Officer. Jean
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)